|Bid||220.50 x 800|
|Ask||220.80 x 800|
|Day's Range||210.25 - 222.40|
|52 Week Range||54.21 - 227.71|
|Beta (5Y Monthly)||1.47|
|PE Ratio (TTM)||148.36|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Shares of Moderna (NASDAQ: MRNA) jumped 6.3% higher as of the market close on Tuesday. The solid gain came after the company announced that the European Commission (EC) has agreed to buy an additional 150 million doses of its COVID-19 vaccine, bringing the total number of doses ordered by the EC to 460 million. Moderna announced an even bigger purchase last week with the U.S. government signing an agreement to buy 200 million additional doses of the company's COVID-19 vaccine.
Moderna (MRNA) plans to increase its COVID-19 vaccine production capacity to meet the growing demand for doses, according to a Wall Street Journal report citing company officials. Moderna's stock jumped 4.54% on Monday to close at $208.24. The company is setting up two new production lines at its U.S. plant in Boston. The first line is expected to begin production by fall, while the second line will start by early 2022. These lines will ramp up the facility’s production capacity by 50%. Moderna
The European Union has decided to take up an option under a supply contract with Moderna Inc (NASDAQ: MRNA) that allows the bloc to order 150 million additional COVID-19 vaccines. This purchase brings the European Commission's confirmed order commitment to 460 million doses. The announcement comes a week after CureVac BV's (NASDAQ: CVAC) COVID-19 vaccine was only 47% effective in a late-stage trial, missing the study's primary goal and casting doubt on the potential delivery of doses to the E.U.